ELDN
$2.88
Eledon Pharmaceuticals, Inc.
Recent News
Eledon Pharmaceuticals Touts Tegoprubart Safety in BESTOW Kidney Transplant Data at Leerink Conference
Eledon Pharmaceuticals (NASDAQ:ELDN) used a presentation at the Leerink Partners Global Healthcare Conference to highlight what CEO David-Alexandre Gros described as a rapid expansion in clinical experience with its lead CD40 ligand antibody, tegoprubart, across multiple transplant settings. Gros sa
NewcelX and Eledon partner for NCEL-101 programme
The partnership draws on clinical experience from over 100 transplant patients treated with tegoprubart.
Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for “Tego” at Conference
Eledon Pharmaceuticals (NASDAQ:ELDN) executives discussed recent clinical results and upcoming regulatory plans for its investigational immunosuppressive therapy, referred to in the discussion as “tego,” highlighting data from the company’s Phase II BESTOW kidney transplant study, longer-term follow
Assessing Eledon Pharmaceuticals (ELDN) Valuation After Phase 2 Kidney Transplant Trial Results and Phase 3 Prospects
Eledon Pharmaceuticals (ELDN) just shared results from its Phase 2 BESTOW trial on tegoprubart for kidney transplant rejection. While the main goal was not fully met, the data points to meaningful preservation of kidney function. See our latest analysis for Eledon Pharmaceuticals. Shares of Eledon Pharmaceuticals have taken a steep dive recently, with the share price dropping over 49% in a single day and more than 52% over the past week following news from the Phase 2 trial. This latest...
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) is largely controlled by institutional shareholders who own 51% of the company
Key Insights Given the large stake in the stock by institutions, Eledon Pharmaceuticals' stock price might be...